WO2023203374 - [1,2]SELENAZOLO[2,3-A]PYRIDIN-8-IUM INHIBITORS OF PYRUVATE KINASE ISOFORM M2
National phase entry:
Publication Number
WO/2023/203374
Publication Date
26.10.2023
International Application No.
PCT/IB2022/061762
International Filing Date
05.12.2022
Title **
[English]
[1,2]SELENAZOLO[2,3-A]PYRIDIN-8-IUM INHIBITORS OF PYRUVATE KINASE ISOFORM M2
[French]
COMPOSÉS DE TYPE [1,2]SELENAZOLO[2,3-A]PYRIDIN-8-IUM INHIBITEURS DE L'ISOFORME M2 DE LA PYRUVATE KINASE
Applicants **
LATVIAN INSTITUTE OF ORGANIC SYNTHESIS
Inventors
ARSENJANS, Pavels
DIMITRIJEVS, Pavels
MAKRECKA-KUKA, Marina
Priority Data
LVP2022000034
20.04.2022
LV
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2053 | |
| EPO | Filing, Examination, Granting | 8624 | |
| Japan | Filing, Examination, Granting | 2183 | |
| South Korea | Filing, Examination, Granting | 2133 | |
| USA | Filing, Examination, Granting | 11940 |
Total:
26,933
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention relates to a novel isoselenazolopyridinium salts as anticancer agents by inhibiting pyruvate kinase isoform M2 (PKM2) activity, as well as methods of their manufacturing and use in different pharmaceutical compositions for the treatment of various diseases and disorders by administration of such substances.[French]
La présente invention concerne de nouveaux sels d'isoselenazolopyridinium agissant comme agents anticancéreux par inhibition de l'activité de l'isoforme M2 de la pyruvate kinase (PKM2), ainsi que leurs procédés de fabrication et d'utilisation dans différentes compositions pharmaceutiques pour le traitement de diverses maladies et de divers troubles par administration de telles substances.